Document:

LEXINGTON REALTY TRUST,

as Issuer,

 

CERTAIN SUBSIDIARIES OF LEXINGTON REALTY
TRUST,

 

as Guarantors,

 

and

 

U.S. BANK NATIONAL ASSOCIATION,

as Trustee

 

 

 

Supplemental Indenture No. 1

 

Dated as of May 20, 2014

 

 

 

$250,000,000

 

of

 

4.40% Senior Notes due 2024

 

    	 

    	 

    

 

TABLE OF
CONTENTS

 

	 	 	Page
	 	 	 
	Article One RELATION TO BASE INDENTURE; DEFINITIONS SECTION	1
	 	 	 
	Section 1.1	Relation to Base Indenture	1
	 	 	 
	Section 1.2	Definitions	2
	 	 	 
	Article Two THE NOTES SECTION	5
	 	 	 
	Section 2.1	Title of the Securities	5
	 	 	 
	Section 2.2	Forms Generally	5
	 	 	 
	Section 2.3	Limitation on Initial Aggregate Principal Amount; Further Issuances	5
	 	 	 
	Section 2.4	Interest and Interest Rates; Maturity Date of Notes	5
	 	 	 
	Section 2.5	Issuance of Additional Notes	6
	 	 	 
	Section 2.6	Limitations on Incurrence of Debt	6
	 	 	 
	Section 2.7	Insurance	8
	 	 	 
	Section 2.8	Maintenance of Properties	8
	 	 	 
	Section 2.9	Payment of Taxes and Other Claims	8
	 	 	 
	Section 2.10	Optional Redemption	9
	 	 	 
	Section 2.11	Execution and Delivery of Guarantee	9
	 	 	 
	Section 2.12	No Sinking Fund	9
	 	 	 
	Section 2.13	Conflict with Trust Indenture Act	9
	 	 	 
	Article Three MISCELLANEOUS PROVISIONS SECTION	9
	 	 	 
	Section 3.1	Ratification of Base Indenture	9
	 	 	 
	Section 3.2	Governing Law	10
	 	 	 
	Section 3.3	Counterparts	10
	 	 	 
	Section 3.4	Trustee	10
	 	 	 
	Section 3.5	Corporate Trust Office	10
	 	 	 
	Section 3.6	Failure or Delay in Performance	10
	 	 	 
	Section 3.7	Effect of First Supplemental Indenture	10
	 	 	 
	Section 3.8	Effect of Headings	11
	 	 	 
	Section 3.9	Successors and Assigns	11
	 	 	 
	Section 3.10	Severability Clause	11
	 	 	 
	Section 3.11	Benefits of First Supplemental Indenture	11
	 	 	 
	Section 3.12	WAIVER OF JURY TRIAL	11
	 	 	 
	Section 3.13	Electronic Notices	11

 

    	i

    	 

    

 

	EXHIBIT A	Form of Note	A-1
	 	 	 
	EXHIBIT B	Form of Guarantee	B-1

 

    	ii

    	 

    

 

THIS SUPPLEMENTAL INDENTURE NO. 1, dated
as of May 20, 2014 (the “First Supplemental Indenture”), between LEXINGTON REALTY TRUST, a Maryland real
estate investment trust, (the “Issuer”), and U.S. BANK NATIONAL ASSOCIATION, a national banking association,
as trustee (herein called the “Trustee”).

 

WITNESSETH:

 

WHEREAS, the Issuer has heretofore
delivered to the Trustee an Indenture dated as of May 9, 2014 (the “Base Indenture”), providing for the issuance
by the Issuer from time to time of its senior debt securities evidencing its unsecured and unsubordinated indebtedness (the “Securities”).

 

WHEREAS, Section 2.01 of the
Base Indenture provides for various matters with respect to any series of Securities issued under the Base Indenture to be established
in an indenture supplemental to the Base Indenture.

 

WHEREAS, Section 9.01(i) of
the Base Indenture provides for the Issuer and the Trustee to enter into an indenture supplemental to the Base Indenture to establish
the form or terms of Securities of any series as provided by Sections 2.01 and 2.02 of the Base Indenture.

 

WHEREAS, the Board of Trustees of
Lexington Realty Trust, has duly adopted resolutions authorizing the Issuer to execute and deliver this First Supplemental Indenture;
and

 

WHEREAS, all of the conditions and
requirements necessary to make this First Supplemental Indenture, when duly executed and delivered, a valid and binding agreement
in accordance with its terms and for the purposes herein expressed, have been performed and fulfilled.

 

NOW, THEREFORE, THIS FIRST SUPPLEMENTAL
INDENTURE WITNESSETH:

 

For and in consideration of the premises
and the purchase of the series of Securities provided for herein by the Holders thereof, it is mutually covenanted and agreed,
for the equal and proportionate benefit of all Holders of Securities of such series, as follows:

 

Article
One

RELATION TO BASE INDENTURE; DEFINITIONS SECTION

 

Section 1.1     Relation
to Base Indenture.

 

This First Supplemental Indenture constitutes
an integral part of the Base Indenture.

 

    	1

    	 

    

 

Section 1.2     Definitions.

 

For all purposes of this First Supplemental
Indenture, except as otherwise expressly provided for or unless the context otherwise requires:

 

(1)     Capitalized
terms used but not defined herein shall have the respective meanings assigned to them in the Base Indenture; and

 

(2)     All
references herein to Articles and Sections, unless otherwise specified, refer to the corresponding Articles and Sections of this
First Supplemental Indenture.

 

"Acquired Debt" means Debt
of a Person (1) existing at the time such Person is merged or consolidated with or into the Issuer or any of its Subsidiaries
or becomes a Subsidiary of the Issuer; or (2) assumed by the Issuer or any of its Subsidiaries in connection with the acquisition
of assets from such Person. Acquired Debt shall be deemed to be incurred on the date the acquired Person is merged or consolidated
with or into the Issuer or any of its Subsidiaries or becomes a Subsidiary of the Issuer or the date of the related acquisition,
as the case may be.

 

"Additional Notes" means
additional Notes (other than the Initial Notes) issued under this First Supplemental Indenture in accordance with Section 2.5
hereof, as part of the same series as the Initial Notes.

 

"Adjusted Treasury Rate"
means, with respect to any Redemption Date, the rate per year equal to the semi-annual equivalent yield to maturity (computed on
the third Business Day immediately preceding the Redemption Date) of the Comparable Treasury Issue, assuming a price for the Comparable
Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date.

 

"Annual Debt Service Charge"
means, for any period, the interest expense of the Issuer and its Subsidiaries for such period, determined on a consolidated basis
in accordance with United States generally accepted accounting principles.

 

"Comparable Treasury Issue"
means the United States Treasury security selected by the Quotation Agent as having an actual or interpolated maturity comparable
to the remaining term of the Notes to be redeemed that would be utilized, at the time of selection and in accordance with customary
financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such Notes.

 

"Comparable Treasury Price"
means, with respect to any Redemption Date, (1) the average of the Reference Treasury Dealer Quotations for such Redemption
Date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, (2) if the Trustee obtains fewer
than four such Reference Treasury Dealer Quotations, the average of all such Quotations or (3) if only one Reference Treasury Dealer
Quotation is received, such quotation.

 

"Consolidated Income Available for
Debt Service" means, for any period, Consolidated Net Income of the Issuer and its Subsidiaries for such period, plus
amounts which have been deducted and minus amounts which have been added for, without duplication: (1) interest expense on
Debt, (2) provision for taxes based on income, (3) amortization of debt discount, premium and deferred financing costs,
(4) impairment losses and gains on sales or other dispositions of properties and other investments, (5) real estate related
depreciation and amortization, (6) the effect of any non-recurring non-cash items, and (7) amortization of deferred charges,
(8) gains or losses on early extinguishment of debt, and (9) acquisition expenses, all determined on a consolidated basis
in accordance with United States generally accepted accounting principles.

 

    	2

    	 

    

 

"Consolidated Net Income"
means, for any period, the amount of net income (or loss) of the Issuer and its Subsidiaries for such period, excluding, without
duplication: (1) extraordinary items, and (2) the portion of net income (but not losses) of the Issuer and its Subsidiaries
allocable to minority interests in unconsolidated persons to the extent that cash dividends or distributions have not actually
been received by the Issuer or one of its Subsidiaries, all determined on a consolidated basis in accordance with United States
generally accepted accounting principles.

 

"Debt" means, with respect
to any Person, any indebtedness of such Person in respect of, without duplication, (1) such Person’s borrowed money or such
Person’s indebtedness evidenced by bonds, notes, debentures or similar instruments, in each case, whether or not such Debt
is secured by any Lien existing on any property or assets owned by such Person; (2) any other indebtedness secured by any Lien
on any property or asset owned by such Person, but only to the extent of the lesser of (a) the amount of indebtedness so secured
and (b) the fair market value (determined in good faith by the board of trustees of such Person or, in the case of a Guarantor,
by the Issuer’s Board of Trustees) of the property subject to such Lien; (3) reimbursement obligations, contingent or otherwise,
in connection with any letters of credit actually issued or amounts representing the balance deferred and unpaid of the purchase
price of any property except any such balance that constitutes an accrued expense or trade payable; or (4) any lease of property
by such Person as lessee which is required to be reflected on such Person’s balance sheet as a capitalized lease in accordance
with United States generally accepted accounting principles, other than any operating lease that is re-characterized as an indebtedness
or a liability due to a change in accounting treatment pursuant to United States generally accepted accounting principles. The
term "Debt" also includes, to the extent not otherwise included, any non-contingent obligation of such Person to be liable
for, or to pay, as obligor, guarantor or otherwise (other than for purposes of collection in the ordinary course of business),
Debt of the types referred to above of another Person (it being understood that Debt shall be deemed to be incurred by such Person
whenever such Person shall create, assume, guarantee (on a non-contingent basis) or otherwise become liable in respect thereof).

 

"Holders" has the meaning
specified in Section 2.4 hereof.

 

“Indenture” means the
Base Indenture together with the First Supplemental Indenture.

 

"Initial Notes" means the
first $250,000,000 aggregate principal amount of Notes issued under this First Supplemental Indenture on the date hereof.

 

"Interest Payment Date"
has the meaning specified in Section 2.3 hereof.

 

"Lien" means any mortgage,
deed of trust, lien, charge, pledge, security interest, security agreement, or other encumbrance of any kind.

 

"Maturity Date" has the
meaning specified in Section 2.4 hereof.

 

"Notes" has the meaning
specified in Section 2.1 hereof.

 

    	3

    	 

    

 

"Primary Treasury Dealer"
means a primary U.S. Government securities dealer.

 

"Quotation Agent" means
the Reference Treasury Dealer appointed by the Issuer

 

"Record Date" has the meaning
specified in Section 2.4 hereof.

 

"Reference Treasury Dealer"
means (1) a Primary Treasury Dealer selected by Wells Fargo Securities LLC or its successor, (2) J.P. Morgan Securities LLC or
its successor and (3) any one other Primary Treasury Dealer selected by the Issuer; provided, however, that if any of the Reference
Treasury Dealers referred to in clause (1), (2) or (3) above ceases to be a Primary Treasury Dealer, the Issuer will substitute
therefor another Primary Treasury Dealer.

 

"Reference Treasury Dealer Quotations"
means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Issuer, of the
bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted
in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the third Business Day preceding
such Redemption Date.

 

"Redemption Price" has
the meaning provided in Section 2.10 hereof.

 

"Total Assets" means the
sum of, without duplication (1) Undepreciated Real Estate Assets and (2) all other assets (excluding accounts receivable
and non-real estate intangibles) of the Issuer and its Subsidiaries, all determined on a consolidated basis in accordance with
United States generally accepted accounting principles.

 

"Total Unencumbered Assets"
means, as of any date, the Total Assets of the Issuer and its Subsidiaries, which are not subject to a Lien securing Debt, all
determined on a consolidated basis in accordance with United States generally accepted accounting principles; provided, however,
that, in determining Total Unencumbered Assets as a percentage of outstanding Unsecured Debt for purposes of the covenant set forth
in Section 2.6(d) hereof entitled "Maintenance of Total Unencumbered Assets," all investments in unconsolidated
limited partnerships, unconsolidated limited liability companies and other unconsolidated entities shall be excluded from Total
Unencumbered Assets.

 

"Undepreciated Real Estate Assets"
means, as of any date, the cost (original cost plus capital improvements) of real estate assets and related intangibles of the
Issuer and its Subsidiaries on such date, before depreciation and amortization, all determined on a consolidated basis in accordance
with United States generally accepted accounting principles.

 

"Unsecured Debt" means
Debt of the Issuer or any of its Subsidiaries which is not secured by a Lien on any property or assets of the Issuer or any of
its Subsidiaries.

 

    	4

    	 

    

 

Article
Two

THE NOTES SECTION

 

Section 2.1     Title
of the Securities.

 

There shall be a series of Securities designated
the “4.40% Senior Notes due 2024” (the “Notes”).

 

Section 2.2     Forms
Generally.

 

The Notes and the Trustee’s certificate
of authentication shall be in the forms set forth in Exhibit A attached hereto, with such appropriate insertions, omissions,
substitutions and other variations as are required or permitted by the Base Indenture and may have such letters, numbers or other
marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities
exchange or as may, consistently herewith, be determined by the officers executing such Notes, as evidenced by their execution
of the Notes. Any portion of the text of any Note may be set forth on the reverse thereof, with an appropriate reference thereto
on the face of the Note.

 

The Notes shall be printed, lithographed
or engraved or produced by any combination of these methods or may be produced in any other manner, as determined by the officers
of the Issuer executing such Notes, as evidenced by their manual execution of such Notes.

 

Upon the execution of this First Supplemental
Indenture, and from time to time thereafter, Notes may be executed by the Issuer and delivered to the Trustee for authentication,
and the Trustee shall thereupon authenticate and deliver Notes upon a written order of the Issuer conforming to the signatory requirements
of an Officers’ Certificate under Section 1.1 of the Base Indenture (an "Authentication Order"), without
any further action by the Issuer hereunder.

 

Section 2.3     Limitation
on Initial Aggregate Principal Amount; Further Issuances.

 

The aggregate principal amount of the Initial
Notes shall be limited to $250,000,000, except as provided in Sections 2.06 and 2.07 of the Base Indenture. The Issuer may, from
time to time, subject to Section 2.6 hereof and applicable law, create and issue Additional Notes under the Indenture.

 

Section 2.4     Interest
and Interest Rates; Maturity Date of Notes.

 

The Notes shall bear interest at 4.40% per
annum from May 20, 2014 or from the immediately preceding Interest Payment Date (as defined below) to which interest has been paid,
payable semi-annually in arrears on June 15 and December 15 of each year, commencing December 15, 2014 (each, an “Interest
Payment Date”), to the persons (the “Holders”) in whose name the applicable Notes are registered in
the Security Register at the close of business 15 calendar days prior to such Interest Payment Date (regardless of whether such
day is a Business Day, as defined below), as the case may be (each, a “Record Date”). Interest on the Notes
shall be computed on the basis of a 360-day year of twelve 30-day months. Defaulted Interest, if any, shall forthwith cease to
be payable to the Holder on the applicable Record Date and may either be paid to the person in whose name such Note is registered
at the close of business on a special record date for the payment of such Defaulted Interest to be fixed by the Trustee, notice
of which shall be given to the Holder of such Note not less than ten days prior to such special record date, or may be paid at
any time in any other lawful manner, as more particularly described in the Base Indenture. The Notes shall mature on June 15, 2024
(the “Maturity Date”).

 

    	5

    	 

    

 

 

Section 2.5     Issuance
of Additional Notes.

 

The Issuer will be entitled, upon delivery
to the Trustee of an Officers' Certificate, Opinion of Counsel and Authentication Order, subject to its compliance with Section
2.6 hereof, to issue Additional Notes under the Indenture that will have identical terms to and the same CUSIP number as the
Initial Notes issued on the date of this First Supplemental Indenture other than with respect to the date of issuance, issue price,
the date from which interest accrues on such Additional Notes, and if applicable, the first interest payment date. The Initial
Notes and any such Additional Notes will constitute a single series of debt securities, and in circumstances in which the Indenture
provides for the Holders of Notes to vote or take any action, the Holders of Initial Notes and the Holders of any such Additional
Notes will vote or take the action as a single class.

 

With respect to any Additional Notes, the
Issuer will set forth in a resolution of its Board of Trustees and an Officers’ Certificate, a copy of each of which will
be delivered to the Trustee, the following information:

 

  (1)     the
aggregate principal amount of such Additional Notes to be authenticated and delivered pursuant to the Indenture; and

 

  (2)     the
issue price, the issue date and the CUSIP number of such Additional Notes.

 

Section 2.6     Limitations
on Incurrence of Debt.

 

(a)     Limitation
on Total Outstanding Debt. The Issuer will not, and will not permit any of its Subsidiaries to, incur any Debt (including,
without limitation, Acquired Debt) if, immediately after giving effect to the incurrence of such Debt and the application of the
proceeds from such Debt on a pro forma basis, the aggregate principal amount of all of the Issuer’s and its Subsidiaries’
outstanding Debt (determined on a consolidated basis in accordance with United States generally accepted accounting principles)
is greater than 60% of the sum of the following (without duplication): (1) the Issuer’s and its Subsidiaries’
Total Assets as of the last day of the then most recently ended fiscal quarter and (2) the aggregate purchase price of any
real estate assets or mortgages receivable acquired, and the aggregate amount of any securities offering proceeds received (to
the extent such proceeds were not used to acquire real estate assets or mortgages receivable or used to reduce Debt), by the Issuer
or any Subsidiary of the Issuer since the end of such fiscal quarter, including the proceeds obtained from the incurrence of such
additional Debt.

 

    	6

    	 

    

 

 

(b)     Limitation
on Secured Debt. The Issuer will not, and will not permit any of its Subsidiaries to, incur any Debt (including, without limitation,
Acquired Debt) secured by any Lien on any of the Issuer’s or any of its Subsidiaries’ property or assets, whether owned
on the date of this First Supplemental Indenture or subsequently acquired, if, immediately after giving effect to the incurrence
of such Debt and the application of the proceeds from such Debt on a pro forma basis, the aggregate principal amount of all of
the Issuer’s and its Subsidiaries’ outstanding Debt (determined on a consolidated basis in accordance with United States
generally accepted accounting principles) which is secured by a Lien on any of the Issuer’s or its Subsidiaries’ property
or assets is greater than 40% of the sum of (without duplication): (1) the Issuer’s and its Subsidiaries’ Total
Assets as of the last day of the then most recently ended fiscal quarter; and (2) the aggregate purchase price of any real
estate assets or mortgages receivable acquired, and the aggregate amount of any securities offering proceeds received (to the extent
such proceeds were not used to acquire real estate assets or mortgages receivable or used to reduce Debt), by the Issuer or any
of its Subsidiaries since the end of such fiscal quarter, including the proceeds obtained from the incurrence of such additional
Debt.

 

(c)     Debt
Service Test.

 

  (1)     The
Issuer will not, and will not permit any of its Subsidiaries to, incur any Debt (including, without limitation, Acquired Debt)
if the ratio of Consolidated Income Available for Debt Service to Annual Debt Service Charge for the period consisting of the four
consecutive fiscal quarters most recently ended prior to the date on which such additional Debt is to be incurred shall have been
less than 1.5:1 on a pro forma basis after giving effect to the incurrence of such Debt and the application of the proceeds from
such Debt (determined on a consolidated basis in accordance with United States generally accepted accounting principles), and calculated
on the following assumptions:

 

    (A)     such
Debt and any other Debt (including, without limitation, Acquired Debt) incurred by the Issuer or any of its Subsidiaries since
the first day of such four- quarter period had been incurred, and the application of the proceeds from such Debt (including to
repay or retire other Debt) had occurred, on the first day of such period;

 

    (B)     the
repayment or retirement of any other Debt of the Issuer or any of its Subsidiaries since the first day of such four-quarter period
had occurred on the first day of such period (except that, in making this computation, the amount of Debt under any revolving credit
facility, line of credit or similar facility will be computed based upon the average daily balance of such Debt during such period);
and

 

    (C)     in
the case of any acquisition or disposition by the Issuer or any of its Subsidiaries of any asset or group of assets with a fair
market value in excess of $1.0 million since the first day of such four-quarter period, whether by merger, stock purchase or sale
or asset purchase or sale or otherwise, such acquisition or disposition had occurred as of the first day of such period with the
appropriate adjustments with respect to such acquisition or disposition being included in such pro forma calculation.

 

    	7

    	 

    

 

  (2)     If
the Debt giving rise to the need to make the calculation described in Section 2.6(c)(1) hereof or any other Debt incurred
after the first day of the relevant four-quarter period bears interest at a floating rate, then, for purposes of calculating the
Annual Debt Service Charge, the interest rate on such Debt will be computed on a pro forma basis by applying the average daily
rate which would have been in effect during the entire four-quarter period to the greater of the amount of such Debt outstanding
at the end of such period or the average amount of such Debt outstanding during such period. For purposes of this Section 2.6(c)
hereof, Debt will be deemed to be incurred by the Issuer or any of its Subsidiaries whenever the Issuer or any of its Subsidiaries
shall create, assume, guarantee (on a non-contingent basis) or otherwise become liable in respect thereof.

 

(d)     Maintenance
of Total Unencumbered Assets. The Issuer and its Subsidiaries will not have at any time Total Unencumbered Assets of less than
150% of the aggregate principal amount of all of the Issuer’s and its Subsidiaries’ outstanding Unsecured Debt determined
on a consolidated basis in accordance with United States generally accepted accounting principles.

 

Section 2.7     Insurance.

 

The Issuer will, and will cause of each
of its Subsidiaries to, keep in force upon all of the Issuer’s and each of its Subsidiaries’ properties and operations
insurance policies carried with responsible insurance companies in such amounts and covering all such risks as is customary in
the industry in which the Issuer and its Subsidiaries do businesses in accordance with prevailing market conditions and availability.

 

Section 2.8     Maintenance
of Properties.

 

The Issuer will cause all of its and its
Subsidiaries’ properties used or useful in the conduct of the business of the Issuer or any of its Subsidiaries to be maintained
and kept in good condition, repair and working order and supplied with all necessary equipment and the Issuer will cause all necessary
repairs, renewals, replacements, betterments and improvements to be made, all as in the Issuer’s judgment may be necessary
in order for the Issuer to at all times properly and advantageously conduct its business carried on in connection with such properties.

 

Section 2.9     Payment
of Taxes and Other Claims.

 

The Issuer will pay or discharge or cause
to be paid or discharged before it becomes delinquent: (i) all taxes, assessments and governmental charges levied or imposed
on the Issuer or any of its Subsidiaries or on its or any such Subsidiary’s income, profits or property; and (ii) all
lawful claims for labor, materials and supplies that, if unpaid, might by law become a Lien upon its property or the property of
any of its Subsidiaries; provided, however, that the Issuer will not be required to pay or discharge or cause to
be paid or discharged any tax, assessment, charge or claim the amount, applicability or validity of which is being contested in
good faith.

 

    	8

    	 

    

 

Section 2.10    Optional
Redemption.

 

(a)     The
Issuer shall have the right to redeem the Notes at its option and in its sole discretion at any time or from time to time prior
to the Maturity Date, in whole or in part. The redemption price (“Redemption Price”) will equal the greater
of (i) 100% of the principal amount of the Notes to be redeemed or (ii) as determined by the Quotation Agent, the sum
of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such
payments of interest accrued as of the Redemption Date) discounted to the Redemption Date on a semi-annual basis (assuming a 360-day
year consisting of twelve 30-day months) at the Adjusted Treasury Rate plus 30 basis points (0.30% or thirtyone-hundredths of one
percent), plus, in each case, accrued and unpaid interest thereon to the applicable Redemption Date; provided, however,
that if the Redemption Date falls after a Record Date and on or prior to the corresponding interest payment date, the Issuer
will pay the full amount of accrued and unpaid interest, if any, on such interest payment date to the Holder of record at the close
of business on the corresponding Record Date (instead of the Holder surrendering its Notes for redemption). Notwithstanding the
foregoing, if the Notes are redeemed on or after March 15, 2024, the Redemption Price will be equal to 100% of the principal amount
of the Notes being redeemed plus unpaid interest, if any, accrued thereon to, but excluding, the Redemption Date.

 

(b)     The
Issuer shall not redeem the Notes pursuant to Section 2.10(a) hereof on any date if the principal amount of the Notes
has been accelerated, and such an acceleration has not been rescinded or cured on or prior to such date (except in the case of
an acceleration resulting from a default by the Issuer in the payment of the Redemption Price with respect to the Notes to be redeemed).

 

Section 2.11    Execution
and Delivery of Guarantee.

 

The Guarantee substantially in the form
of Exhibit B supplemental hereto shall be endorsed on each Security authenticated and delivered by the Trustee under Section
15.02 of the Base Indenture. The delivery of any such Security by the Trustee, after the authentication thereof hereunder, shall
constitute due delivery of the Guarantee set forth in the Indenture on behalf of the Guarantor.

 

Section 2.12    No
Sinking Fund.

 

The provisions of Sections 3.04, 3.05 and
3.06 of the Base Indenture shall not be applicable to the Notes.

 

Section 2.13    Conflict
with Trust Indenture Act.

 

If any provision hereof limits, qualifies
or conflicts with another provision hereof, or with a provision of the Base Indenture, which is required to be included in this
First Supplemental Indenture, or in the Base Indenture, respectively, by any of the provisions of the Trust Indenture Act, such
required provision shall control to the extent it is applicable.

 

Article
Three

MISCELLANEOUS PROVISIONS SECTION

 

Section 3.1     Ratification
of Base Indenture.

 

Except as expressly modified or amended
hereby, the Base Indenture continues in full force and effect and is in all respects confirmed, ratified and preserved.

 

    	9

    	 

    

 

Section 3.2     Governing
Law.

 

This First Supplemental Indenture and each
Note shall be governed by and construed in accordance with the laws of the State of New York. This First Supplemental Indenture
is subject to the provisions of the Trust Indenture Act and shall, to the extent applicable, be governed by such provisions.

 

Section 3.3     Counterparts.

 

This First Supplemental Indenture may be
executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts
shall together constitute but one and the same instrument.

 

Section 3.4     Trustee.

 

The Trustee makes no representations as
to the validity or sufficiency of this First Supplemental Indenture. The statements and recitals herein are deemed to be those
of the Issuer and not of the Trustee.

 

Section 3.5     Corporate
Trust Office.

 

The Trustee hereby notifies the Issuer that
its corporate trust business is principally administered at its office located at100 Wall Street, Suite 1600, New York, New York
10005 and, therefore, pursuant to the Indenture, the Corporate Trust Office is such office.

 

Section 3.6     Failure
or Delay in Performance.

 

In no event shall the Trustee be responsible
or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly,
forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or
military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications
or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent
with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

 

Section 3.7     Effect
of First Supplemental Indenture.

 

This First Supplemental Indenture is a supplemental
indenture within the meaning of Section 9.01 of the Base Indenture, and the Base Indenture shall be read together with this First
Supplemental Indenture and shall have the same effect over the Notes, in the same manner as if the provisions of the Base Indenture
and this First Supplemental Indenture were contained in the same instrument. In all other respects, the Base Indenture is confirmed
by the parties hereto as supplemented by the terms of this First Supplemental Indenture.

 

    	10

    	 

    

 

Section 3.8     Effect
of Headings.

 

The Article and Section headings herein
are for convenience only and shall not affect the construction hereof.

 

Section 3.9     Successors
and Assigns.

 

All covenants and agreements in this First
Supplemental Indenture by the Issuer, the Guarantors, the Trustee and the Holders shall bind their successors and assigns, whether
so expressed or not.

 

Section 3.10     Severability
Clause.

 

In case any provision in this First Supplemental
Indenture or in the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

 

Section 3.11     Benefits
of First Supplemental Indenture.

 

Nothing in this First Supplemental Indenture
or in the Notes, express or implied, shall give to any Person, other than the parties hereto, any benefit or any legal or equitable
right, remedy or claim under this First Supplemental Indenture.

 

Section 3.12     WAIVER
OF JURY TRIAL.

 

EACH OF THE ISSUER AND THE TRUSTEE HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS FIRST SUPPLEMENTAL INDENTURE, THE INDENTURE (TO THE EXTENT IT RELATES TO THE NOTES), THE NOTES
OR THE TRANSACTION CONTEMPLATED HEREBY.

 

Section 3.13     Electronic
Notices.

 

In addition to the foregoing, the Trustee
agrees to accept and act upon notice, instructions or directions pursuant to this First Supplemental Indenture sent by unsecured
e-mail, facsimile transmission or other similar unsecured electronic methods. If the party elects to give the Trustee e-mail or
facsimile instructions (or instructions by a similar electronic method) and the Trustee in its discretion elects to act upon such
instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee shall not be liable
for any losses, costs or expenses arising directly or indirectly from the Trustee’s reliance upon and compliance with such
instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The party providing
electronic instructions agrees to assume all risks arising out of the use of such electronic methods to submit instructions and
directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk
or interception and misuse by third parties.

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this First
Supplemental Indenture to be duly executed all as of the day and year first above written.

 

	 	ISSUER:
	 	LEXINGTON REALTY TRUST, a Maryland real
	 	estate investment trust, as Issuer of the Securities
	 	 	 
	 	By: 	/s/ Joseph S. Bonventre
	 	 	Name: Joseph S. Bonventre
	 	 	Title:   Executive Vice President
	 	 	 
	 	SUBSIDIARY GUARANTOR:
	 	LEPERCQ CORPORATE INCOME FUND L.P.,
	 	a Delaware limited partnership, as a Subsidiary
	 	Guarantor	 
	 	 	 
	 	By:	Lex GP-1 Trust, its general partner, a
	 	 	Delaware statutory trust

 

	 	By:	/s/ Joseph S. Bonventre
	 	 	Name: Joseph S. Bonventre
	 	 	Title:   Vice President

 

[Signature Page to First Supplemental
Indenture]

 

    	12

    	 

    

 

	 	TRUSTEE:
	 	 
	 	U.S. BANK NATIONAL ASSOCIATION,
	 	as Trustee

 

	 	By:	/s/ William G. Keenan	 
	 	Name:  William G. Keenan
	 	Title:    Vice President

 

    	 

    	 

    

 

EXHIBIT A

 

THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE
INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE
TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (1) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT
TO SECTION 2.02 OF THE INDENTURE, (2) THIS GLOBAL NOTE MAY BE EXCHANGED IN WHOLE BUT NOT IN PART PURSUANT TO SECTION 2.05(a) OF
THE INDENTURE, (3) THIS GLOBAL NOTE MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO SECTION 2.08 OF THE INDENTURE
AND (4) THIS GLOBAL NOTE MAY BE TRANSFERRED TO A SUCCESSOR DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE ISSUER.

 

UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES
IN DEFINITIVE FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A
NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK) (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION
OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME
AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH OTHER ENTITY
AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY
OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

 

    	 

    	 

    

 

[“Note” to “Security”]

 

LEXINGTON
REALTY TRUST

4.40% SENIOR NOTES DUE 2024

 

No. 1

 

	CUSIP No.:	529043AD3
	 	 
	ISIN:	US529043AD36

 

$250,000,000

 

Lexington Realty Trust, a Maryland real estate investment trust
(herein called the “the Issuer,” which term includes any successor entity under the Indenture referred to on
the reverse hereof), for value received hereby promises to pay to Cede & Co., or its registered assigns, the principal
sum of TWO HUNDRED FIFTY MILLION DOLLARS ($250,000,000), or such lesser amount as is set forth in the Schedule of Increases or
Decreases In Note on the other side of this Note, on June 15, 2024 at the office or agency of the Issuer maintained for that purpose
in accordance with the terms of the Indenture, in such coin or currency of the United States of America as at the time of payment
shall be legal tender for the payment of public and private debts, and to pay interest, semi-annually on June 15 and December 15
of each year, commencing December 15, 2014, on said principal sum at said office or agency, in like coin or currency, at the rate
per annum of 4.40%, from the June 15 or December 15, as the case may be, next preceding the date to which interest has been paid
or duly provided for, unless no interest has been paid or duly provided for on the Notes, in which case from May 20, 2014 until
payment of said principal sum has been made or duly provided for. The Issuer shall pay interest on any Notes in certificated form
by check mailed to the address of the Person entitled thereto as it appears in the Note Register, or on any Global Note by wire
transfer of immediately available funds to the account of the Depositary or its nominee. The Issuer shall pay interest to Holders
of record on the June 1 or December 1 preceding the applicable or June 15 or December 15 interest payment date, respectively,
in accordance with the terms of the Indenture.

 

The Issuer promises to pay interest on overdue principal, premium,
if any, and (to the extent that payment of such interest is enforceable under applicable law) interest at the rate of 1.0% per
annum above the rate borne by the Notes.

 

Reference is made to the further provisions of this Note set
forth on the reverse hereof and the Indenture governing this Note. Such further provisions shall for all purposes have the same
effect as though fully set forth at this place.

 

This Note shall not be valid or become obligatory for any purpose
until the certificate of authentication hereon shall have been signed manually or by facsimile or other electronic imaging means
by the Trustee or a duly authorized authenticating agent under the Indenture.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Issuer has caused this Note to be duly
executed.

 

Dated: May 20, 2014

 

	 	LEXINGTON REALTY TRUST
	 	 	 	 
	 	By:  	 
	 	 	Name:  	Joseph S. Bonventre
	 	 	Title:	Executive Vice President

 

    	 

    	 

    

 

TRUSTEE’S
CERTIFICATE OF AUTHENTICATION

 

This is one of the Notes described in the within-named Indenture.

 

Dated: May 20, 2014

 

	 	U.S. BANK NATIONAL ASSOCIATION,
	 	as Trustee
	 	 	 
	 	By:  	 
	 	 	Authorized Signatory

 

    	 

    	 

    

 

[FORM OF
REVERSE SIDE OF NOTE]

 

Lexington
Realty Trust

4.40% SENIOR NOTES DUE 2024

 

This Note is one of a duly authorized issue of Notes of the
Issuer, designated as its 4.40% Senior Notes due 2024 (herein called the “Notes”), issued under and pursuant
to an Indenture, dated as of May 9, 2014 as supplemented by the First Supplemental Indenture dated as of May 20, 2014
(the “First Supplemental Indenture”), among the Issuer, the Guarantors and U.S. Bank National Association, as
trustee (herein called the “Trustee”) (herein called the “Indenture”), to which Indenture
and any indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations,
duties and immunities thereunder of the Trustee, the Issuer, the Guarantors and the Holders of the Notes. Defined terms used but
not otherwise defined in this Note shall have the respective meanings ascribed thereto in the Indenture.

 

If an Event of Default (other than an Event of Default specified
in Section 6.01(f), 6.01(g) or 6.01(h) of the Indenture with respect to the Issuer) occurs and is continuing, the principal
of, premium, if any, and accrued and unpaid interest on all Notes may be declared to be due and payable by either the Trustee or
the Holders of at least twenty five percent (25%) in aggregate principal amount of the Notes then outstanding, and, upon said declaration
the same shall be immediately due and payable. If an Event of Default specified in Section 6.01(f), 6.01(g) or 6.01(h) of
the Indenture occurs with respect to the Issuer, the principal of and premium, if any, and interest accrued and unpaid on all the
Notes shall be immediately and automatically due and payable without necessity of further action.

 

The Indenture contains provisions permitting the Issuer and
the Trustee, with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time
outstanding, to execute supplemental indentures adding any provisions to or changing in any manner or eliminating any of the provisions
of the Indenture or of any supplemental indenture or modifying in any manner the rights of the Holders of the Notes, subject to
exceptions set forth in Section 9.02 of the Indenture. Subject to the provisions of the Indenture, the Holders of not less than
a majority in aggregate principal amount of the Notes at the time outstanding may, on behalf of the Holders of all of the Notes,
waive any past Default or Event of Default, subject to exceptions set forth in the Indenture.

 

No reference herein to the Indenture and no provision of this
Note or of the Indenture shall impair, as among the Issuer and the Holder of the Notes, the obligation of the Issuer, which is
absolute and unconditional, to pay the principal of, premium, if any, on and interest on this Note at the place, at the respective
times, at the rate and in the coin or currency herein and in the Indenture prescribed.

 

Interest on the Notes shall be computed on the basis of a 360-day
year of twelve 30-day months.

 

    	 

    	 

    

 

The Notes are issuable in fully registered form, without coupons,
in denominations of $2,000 principal amount and any multiple of $1,000. At the office or agency of the Issuer referred to on the
face hereof, and in the manner and subject to the limitations provided in the Indenture, without payment of any service charge
but with payment of a sum sufficient to cover any tax, assessment or other governmental charge that may be imposed in connection
with any registration or exchange of Notes, Notes may be exchanged for a like aggregate principal amount of Notes of any other
authorized denominations.

 

The Issuer shall have the right to redeem the Notes under certain
circumstances as set forth in Section 3.01, Section 3.02 and Section 3.03 of the Indenture and Section 2.10 of the First Supplemental
Indenture.

 

The Notes are not subject to redemption through the operation
of any sinking fund.

 

Except as expressly provided in Article XV of the Indenture,
no recourse for the payment of the principal of or any premium or interest on this Note, or for any claim based hereon or otherwise
in respect hereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer in the Indenture or any supplemental
indenture or in any Note, or because of the creation of any indebtedness represented thereby, shall be had against any incorporator,
stockholder, partner, member, manager, employee, agent, officer, trustee, director or subsidiary, as such, past, present or future,
of the Guarantors, the Issuer or any of the Issuer’s Subsidiaries or of any successor thereto, either directly or through
the Guarantors, the Issuer or any of the Issuer’s subsidiaries or of any successor thereto, whether by virtue of any constitution,
statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that all
such liability is hereby expressly waived and released as a condition of, and as consideration for, the execution of the Indenture
and the issue of this Note.

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

To assign this Note,
fill in the form below:

 

(I) or (we) assign and transfer this Note
to:__________________________________________________

(Insert assignee’s legal name)

 

	 
	(Insert assignee’s soc. sec. or tax I D. no.)

 

	 
	 
	 
	 
	(Print or type assignee’s name, address and zip code)

 

and irrevocably appoint to
__________________ transfer this Note on the books of the Issuer. The agent may substitute another to act for him.

 

Date: _____________

 

	 	Your Signature: 	 
	 	 	(Sign exactly as your name appears
	 	 	on the face of this Note)

 

	 	*Signature Guarantee: 	 
	 	 	*Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to the Trustee).

 

    	 

    	 

    

 

SCHEDULE
OF EXCHANGES OF INTERESTS IN THE GLOBAL NOTE*

 

The following exchanges
of a part of this Global Note for an interest in another Global Note or for a Definitive Note, or exchanges of a part of another
Global Note or Definitive Note for an interest in this Global Note, have been made:

 

	
        Date of

        Exchange
	 	
        Amount of

        decrease in

        Principal

        Amount

        at maturity of

        this Global Note
	 	
        Amount of

        increase in

        Principal

        Amount

        at maturity of

        this Global Note
	 	
        Principal

        Amount

        at maturity of

        this Global Note

        following such

        decrease (or

        increase)
	 	
        Signature of

        authorized

        signatory

        of Trustee or

        Custodian

	 	 	 	 	 	 	 	 	 

 

 

*     This schedule
should be included only if the Note is issued in global form.

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF GUARANTEE

 

The guarantors listed below (hereinafter referred to as the
“Guarantors,” which term includes any successors or assigns under the Indenture, dated May 9, 2014, among
the Guarantors, the Issuer (as defined below) and U.S. Bank National Association, as trustee (the “Trustee”),
as supplemented by the First Supplemental Indenture, dated May  20, 2014 the “First Supplemental Indenture”),
among the Issuer, the Guarantors and the Trustee (the “Indenture”), has irrevocably and unconditionally, jointly
and severally, guaranteed on a senior unsecured basis the Guarantee Obligations (as defined in Section 15.01 of the Indenture),
which include (i) the due and punctual payment of the principal of, premium, if any, and interest, if any, on the 4.40% Senior
Notes due 2024 (the “Notes”) of Lexington Realty Trust, a Maryland real estate investment trust (the “Issuer”),
whether at maturity, by acceleration, call for redemption or otherwise, the due and punctual payment of interest on the overdue
principal and premium, if any, and (to the extent permitted by law) interest on any interest on the Notes, and the due and punctual
performance of all other obligations of the Issuer, to the Holders (as defined in the First Supplemental Indenture) of the Notes
or the Trustee all in accordance with the terms set forth in Article XV of the Indenture, and (ii) in case of any extension
of time of payment or renewal of any Notes or any such other obligations, that the same shall be promptly paid in full when due
or performed in accordance with the terms of the extension or renewal, whether at maturity, by acceleration, call for redemption
or otherwise.

 

The obligations of the Guarantors to the Holders of the Notes
and to the Trustee pursuant to this Guarantee and the Indenture are expressly set forth in Article XV of the Indenture and reference
is hereby made to such Indenture for the precise terms of this Guarantee.

 

No past, present or future director, trustee, officer, employee,
incorporator, partner, member or stockholder (direct or indirect) of the Guarantors (or any such successor entity), as such, shall
have any liability for any obligations of the Guarantors under this Guarantee or the Indenture or for any claim based on, in respect
of, or by reason of, such obligations or their creation.

 

The Guarantors hereby waive diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the Issuer, any right to require a proceeding first
against the Issuer, the benefit of discussion, protest or notice with respect to the Notes and all demands whatsoever.

 

This is a continuing Guarantee and shall remain in full force
and effect and shall be binding upon the Guarantors and their successors and assigns until full and final payment of all of the
Issuer’s obligations under the Notes and Indenture or until legally discharged in accordance with the Indenture and shall
inure to the benefit of the successors and assigns of the Trustee and the Holders of the Notes, and, in the event of any transfer
or assignment of rights by any Holder of the Notes or the Trustee, the rights and privileges herein conferred upon that party shall
automatically extend to and be vested in such transferee or assignee, all subject to the terms and conditions hereof. This is a
Guarantee of payment and performance and not of collectability.

 

    	 

    	 

    

 

This Guarantee shall not be valid or obligatory for any purpose
until the certificate of authentication on the Note upon which this Guarantee is noted shall have been signed, in the name and
on behalf of the Trustee under the Indenture, manually or by facsimile or other electronic imaging means by one of the authorized
officers of the Trustee under the Indenture or as otherwise permitted under the Indenture.

 

The obligations of the Guarantors under this Guarantee shall
be limited to the extent necessary to insure that it does not constitute a fraudulent conveyance under applicable law.

 

THE TERMS OF ARTICLE XV OF THE INDENTURE ARE INCORPORATED HEREIN
BY REFERENCE.

 

Capitalized terms used herein have the same meanings given in
the Indenture unless otherwise indicated.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Guarantee
to be duly executed as of the day and year first above written.

 

	 	ISSUER:
	 	 
	 	LEXINGTON REALTY TRUST, a Maryland real estate 
	 	investment trust, as Issuer of the Notes

 

	 	By:	 
	 	 	Name:  Joseph S. Bonventre
	 	 	Title:  Executive Vice President

 

	 	SUBSIDIARY GUARANTORS:
	 	 
	 	LEPERCQ CORPORATE INCOME FUND L.P.,
	 	a Delaware limited partnership, as a Subsidiary 
	 	Guarantor

 

	 	By:	Lex GP-1 Trust, its general partner, a Delaware
	 	 	statutory trust

 

	 	By:	 
	 	 	Name:  Joseph S. Bonventre
	 	 	Title:  Vice President

 

    	 

    	 

    

 

	 	TRUSTEE:
	 	 
	 	U.S. BANK NATIONAL ASSOCIATION,
	 	as Trustee

 

	 	By:	 	 
	 	Name: William G. Keenan
	 	Title: Vice PresidentEXHIBIT 10.1

 

 

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase
Agreement (“Agreement”), dated as of April 29, 2014 (the “Effective Date”), is entered into
by and between Memory Dx, LLC, an Arizona limited liability company (“MDx”), and Amarantus Bioscience Holdings
Inc., a Nevada corporation (“Amarantus”).

 

RECITALS

 

A.MDx desires to
transfer and assign to Amarantus certain of its assets related to LymPro Technology (as defined below), and Amarantus desires to
purchase such assets on the terms and conditions of this Agreement.

 

Accordingly, in consideration
of the representations, warranties and agreements herein contained, the parties agree as follows:

 

AGREEMENT

 

1.Transfer and
Assignment of Assets. Subject to the terms and conditions of this Agreement, effective as of the Closing Date (as defined below),
MDx shall transfer, assign, contribute, convey and deliver to Amarantus all of MDx’s right, title and interest in and to
all of the rights, properties, goodwill and assets of MDx of every nature, kind and description, tangible and intangible, wherever
located, whether or not carried on the books of MDx (“Transferred Assets”), except those assets expressly identified
as Excluded Assets on Schedule 1 attached hereto (the “Excluded Assets”), which shall remain with MDx. “LymPro
Technology” means any and all cell-based technique for the detection, diagnosis or prognostic testing related to any
neurodegenerative disorder, including without limitation, Alzheimer’s Disease. The Transferred Assets specifically include,
without limitation:

 

1.1all of the intellectual
property owned by MDx as of the Closing Date (the “Intellectual Property”), including:

 

(a)any and all patents
and patent applications (respectively issued or filed throughout the world), owned by MDx as of the Closing Date, as well as any
extensions, divisions, continuations and continuation-in-parts thereof and any applications or patents that claim priority from
such patents and applications, including, without limitation, any foreign counterparts of such patents, in each case related to
the LymPro Technology;

 

(b)the copyrights
owned by MDx as of the Closing Date related to the LymPro Technology;

 

(c)all other intellectual
property and technology, including, without limitation, know-how, trade secrets, inventions (whether or not patented), data, techniques,
materials, clinical and pre-clinical protocols, case report forms, regulatory correspondence, written authorization to access regulatory
correspondence for Amarantus, designs, formulas, processes, procedures, methods, source code, software, databases, works of authorship,
and all documentation and information relating to the design, manufacture, testing, installation, operation, repair, maintenance,
support and use of the LymPro Technology, including without limitation any and all discoveries, improvements and inventions which
are owned by MDx pursuant to Section 4.5 of the Leipzig Agreement (as defined in Section 4);

 

    	Page 1
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

(d)the right to sue
and recover damages for past, present and future infringement of any intellectual property.

 

1.2all computers,
hard drives, removable storage media and records incorporating the Intellectual Property.

 

If either (i) a
material “Transferred Asset” that falls within the definition of “Transferred Asset” was not transferred
to Amarantus as of the Closing, or (ii) a material asset that does not fall within the definition of a “Transferred
Asset” was inadvertently transferred to Amarantus, then MDx or Amarantus, as the case may be, shall promptly, without payment
of consideration, transfer and assign such asset to the party who was intended to receive or retain such asset, as the case may
be, which transfer or receipt, as the case may be, shall be deemed to have been effective as of the Closing Date.

 

2.Liabilities.
Amarantus shall not assume and shall not be deemed to have assumed or be liable or responsible for any debt, obligation, duty or
liability of MDx or any affiliate of MDx, whether known or unknown, fixed or contingent, certain or uncertain (collectively, the
“Liabilities”), and MDx shall remain responsible for all Liabilities.

 

3.Consideration.
The assignment and transfer of the Transferred Assets to Amarantus are made in consideration of:

 

3.1Fifty thousand
dollars ($50,000) payable by Amarantus to MDx on the Effective Date;

 

3.2Fifty thousand
dollars ($50,000) payable by Amarantus to MDx sixty (60) days after the Effective Date;

 

3.3Fifty thousand
dollars ($50,000) payable by Amarantus to MDx one hundred twenty (120) days after the Effective Date; and

 

3.4the issuance by
Amarantus of one million five hundred thousand (1,500,000) shares of Amarantus Rule 144 common stock, with piggy-back registration
rights, to MDx (the “Shares”) upon delivery by MDx of the Transferred Assets.

 

4.Contingent
Consideration. MDx entered into that certain License Agreement with the University of Leipzig as of May 22, 2003, as amended
in May 2004, March 2006, and June 2013, (the “Leipzig Agreement”) which license is included among the Excluded Assets.
MDx granted a sublicense under the Leipzig Agreement to Amarantus in that certain Exclusive License Agreement entered into by Amarantus
and MDx in December 2012 (the “Sublicense Agreement”). Amarantus may then negotiate a direct license from the University
of Leipzig (“Leipzig”) for any and all intellectual property rights included in the Leipzig Agreement (including the
LymPro Technology). If Amarantus comes to agreement with Leipzig, acceptable to Amarantus in its sole discretion, as to terms and
conditions under which the University of Leipzig would grant a direct license to Amarantus, then, upon request by Amarantus, Amarantus
would terminated the Sublicense Agreement and MDx agrees to terminate the Leipzig Agreement. Notwithstanding the foregoing, MDx
will not terminate the Leipzig Agreement without Amarantus’ prior written consent for so long as . If Amarantus enters into
a direct license with Leipzig for the intellectual property rights included in the Leipzig Agreement, and MDx terminates the Leipzig
Agreement, then Amarantus would pay the following additional consideration to MDx:

 

    	Page 2
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

4.1Six million
five hundred thousand (6,500,000) shares of Amarantus Rule 144 common stock, with piggy-back registration rights, to be issued
by Amarantus within 10 business days after execution by Amarantus and Leipzig of a direct license agreement granting rights to
Amarantus to the intellectual property licensed under the Leipzig Agreement (including the LymPro Technology.

 

5.Closing and
Closing Deliverables.

 

5.1The transfer,
assignment, contribution, conveyance and delivery will be effected by delivery by MDx to Amarantus of the duly executed Bill of
Sale and Conveyance (attached hereto as Exhibit A) and such other good and sufficient instruments of conveyance and transfer,
as shall be necessary to vest in Amarantus good and marketable title to the Transferred Assets, free and clear of all claims, liens
and encumbrances, except for those listed on Schedule 1 attached hereto. The closing of the transactions contemplated by
this Agreement will take place (either in person or remotely by electronic exchange of documents) on April 29, 2014, or such other
date as MDx and Amarantus may mutually agree upon in writing (the “Closing”). The date on which the Closing
actually occurs is hereinafter referred to as the “Closing Date.”

 

5.2MDx will not retain
any Transferred Assets, including any copies thereof, after the Closing Date.

 

5.3Upon the Closing
Date, the parties agree that certain Laboratory Services Agreement dated as of April 2, 2013 (the “Lab Services Agreement”)
will be terminated, and no further payments shall be due MDx under the Lab Services Agreement. MDx hereby releases from any and
all claims and liabilities arising under the Lab Services Agreement.

 

6.Representations
and Warranties of MDx. MDx hereby represents and warrants to Amarantus as follows:

 

6.1Corporate Authority.
MDx has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by MDx and the consummation by MDx of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on the part of MDx. This Agreement has been duly executed and delivered
by MDx and constitutes a valid and binding obligation of MDx enforceable in accordance with its terms.

 

6.2Ownership of
Assets; Sufficiency.

 

6.2.1MDx has, and
is transferring to Amarantus, good and marketable title to the Transferred Assets, free and clear of any lien or other encumbrance,
except for those listed on Schedule 1 attached hereto. Without limiting the generality of the foregoing, MDx is the sole
creator of the Intellectual Property and owns all right, title and interest in each item thereof. No part of the Intellectual Property
constitutes “work made for hire” for customers or clients. MDx has not granted to any party any license, agreement
or permission to use the Intellectual Property, except as listed on Schedule 1 attached hereto. MDx has no knowledge that
the Intellectual Property is being infringed by any other party. No claim is pending or, to MDx’s knowledge, has been threatened
to the effect that the Intellectual Property infringes on the rights of any third party or contesting the ownership, validity,
license or use of the Intellectual Property. None of the Transferred Assets are co-owned by MDx and Leipzig.

 

    	Page 3
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

 

6.2.2The Transferred
Assets constitute all of the assets, properties and rights, except for the Excluded Assets, that are necessary and sufficient to
develop and commercialize the LymPro Technology in substantially the manner as currently conducted or contemplated to be conducted,
in each case, on the date hereof by MDx.

 

6.3Non-Contravention.
The execution, delivery and performance by MDx of this Agreement, and the consummation of the transactions contemplated by this
Agreement by MDx will not (i) contravene, conflict with or result in a violation of any of the provisions of the charter,
bylaws or other organizational document of MDx; or (ii) contravene or conflict with or constitute a violation of any provision
of any law, judgment, injunction, order or decree binding upon or applicable to MDx or relating to or affecting the Transferred
Assets.

 

6.4Intellectual
Property.

 

6.4.1Section 6.4.1
of the Disclosure Schedules identifies all Intellectual Property owned or controlled by MDx, including all data related to the
LymPro Technology, other than pursuant to the Excluded Assets.

 

6.4.2Section 6.4.2
of the Disclosure Schedules identifies all computers, hard drives, and removable media among the Transferred Assets.

 

6.4.3MDx has not
filed for registration any application for the registration of Intellectual Property by or on behalf of MDx, and MDx is not a party
to any proceedings or actions before any Governmental or Regulatory Authority relating to any Intellectual Property.

 

6.4.4MDx has provided
to Amarantus true and complete copies of all Intellectual Property, including without limitation all data related to the LymPro
Technology;

 

6.4.5MDx exclusively
owns and possesses all right, title and interest in, free and clear of all Liens (other than Permitted Liens), free and clear of
all Liens, all of the Intellectual Property.

 

6.4.6All current
and former employees, consultants and independent contractors of MDx have entered into a valid and binding Contract with MDx sufficient
to vest title in MDx of all Intellectual Property created by such employees, consultants and independent contractors in the scope
of their employment or engagement with MDx, as applicable.

 

6.4.7There is no
claim by any third Person pending or, to MDx's knowledge, threatened against MDx, contesting the validity, enforceability, or ownership
of any Transferred Assets. The validity or enforceability of the Intellectual Property owned by MDx has not been challenged in
any jurisdiction. To the knowledge of MDx, the Intellectual Property owned by MDx is valid, subsisting, and in full force and effect.

 

6.4.8MDx has not
disclosed, furnished to or made accessible any of its Trade Secrets within the Intellectual Property to any Person who is not subject
to a written agreement to maintain the confidentiality of such Trade Secrets. MDx has, and reasonably enforces, a policy requiring
each employee, consultant and independent contractor to execute a proprietary information, confidentiality and assignment agreement,
and all current and former employees, consultants and independent contractors of MDx that generated, or had access to, Trade Secrets
of MDx in connection with the development of the LymPro Technology have executed such an agreement.

 

    	Page 4
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

 

6.4.9Except as
set forth on Section 6.4.9 of the Disclosure Schedules, to MDx’s knowledge, the development or commercialization of the LymPro
Technology has not, does not and will not infringe, misappropriate, dilute, violate or otherwise conflict with any Intellectual
Property of any other Person or constitute a violation of the Lanham Act, unfair competition or unfair trade practices under the
Law of any jurisdiction. MDx has not received any written notice of any claim (including by an offer to license any Intellectual
Property) and, to MDx’s knowledge, there is no threatened claim, or any basis for any claim (whether or not pending or threatened),
against MDx asserting that MDx infringes upon, misappropriates or otherwise conflicts with the Intellectual Property of any Person
or constitute a violation of the Lanham Act, unfair competition or unfair trade practices under the Laws of any jurisdiction.

 

6.4.10To MDx’s
knowledge, none of the Intellectual Property owned by MDx is being infringed or misappropriated by any Person. MDx has not given
any notice to any Person asserting infringement or misappropriation by any such Person of any of the Intellectual Property.

 

6.4.11Except as
set forth on Schedule 6.4.11 of the Disclosure Schedules, MDx has not received any grant, loan, subsidy, investment or other source
of funding from any Governmental or Regulatory Authority relating to development of the LymPro Technology.

 

6.4.12Debarment.
MDx is not, and has not, in the course of conducting the research and development of the LymPro Technology, used in any capacity
any person who has been debarred under Article 306 of the FDCA, 21 U.S.C. §335a(a) or (b), or any equivalent foreign or local
law, rule or regulation.

 

6.5Indemnification.
MDx hereby agrees to indemnify, defend and hold harmless Amarantus and its successors and assigns from and against any and all
losses, claims, demands, damages, costs and expenses (including, without limitation, reasonable attorneys’ fees and disbursements)
of every kind, nature and description based upon, arising out of or otherwise in respect of: (a) any material inaccuracy or any
material breach of any of the foregoing representations and warranties; (b) any negligent or willful breach of or failure to perform
any covenant, agreement or obligation of MDx in this Agreement or in any Related Agreement; (c) the Liabilities, including the
any and all liabilities accrued in the operation of MDx prior and up to the Closing; or (d) any fraud in connection with, or any
willful breach of, this Agreement or any Related Agreement.

 

6.6Right of Setoff.
Without limiting any other remedies available to Amarantus, Amarantus would have the right to set off any amounts owed by MDx pursuant
to the foregoing indemnification obligations against any amounts owed to MDx under this Agreement.

 

7.Representations
and Warranties of Amarantus. Amarantus hereby represents and warrants to MDx as follows:

 

7.1Corporate Authority.
Amarantus has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and the consummation by Amarantus of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on the part of Amarantus. This Agreement has been duly executed and
delivered by Amarantus and constitutes a valid and binding obligation of Amarantus enforceable in accordance with its terms.

 

7.2Non-Contravention.
The execution, delivery and performance by Amarantus of this Agreement, and the consummation of the transactions contemplated by
this Agreement by Amarantus will not (i) contravene, conflict with or result in a violation of any of the provisions of the
charter, bylaws or other organizational document of Amarantus; or (ii) contravene or conflict with or constitute a violation
of any provision of any law, judgment, injunction, order or decree binding upon or applicable to Amarantus or relating to or affecting
the Transferred Assets.

 

    	Page 5
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

 

8.Other Agreements.

 

8.1Sales Taxes.
MDx and Amarantus acknowledge that no transfer taxes are expected to arise out of the assignment and transfer of the Transferred
Assets by MDx to Amarantus. To the extent such transfer taxes do arise, and to the extent permitted by applicable law, MDx and
Amarantus shall use reasonable best efforts to minimize such transfer taxes, and MDx shall bear and pay any such transfer taxes.

 

8.2Further Assurances.
Each of the parties, for itself and its successors and assigns, hereby covenants and agrees that, without further consideration,
at any time and from time to time after the date hereof, it will cooperate with the other parties to execute and deliver such other
documents and instruments, amend any of the schedules hereto and to take or cause to be taken all such actions as from time to
time may be reasonably requested by such party to obtain the full benefits of this Agreement, to evidence, vest, perfect and confirm,
document, and carry out the assignment and transfer of the Transferred Assets, to ensure the retention by MDx of the Liabilities,
and to effect the consummation of any related transactions referenced in this Agreement.

 

9.General Provisions.

 

9.1Entire Agreement.
This Agreement (including any schedules, exhibits and addenda hereto) and the other documents referred to herein, contain the entire
agreement of the parties with respect to the subject matter of this Agreement and supersedes all previous communications, representations,
understandings and agreements, either oral or written, between the parties with respect to the subject matter. For clarity, the
license agreement between Amarantus and MDx dated [] shall remain in full force and effect. This Agreement may not be altered or
amended except by a written instrument signed by the authorized legal representatives of both parties.

 

9.2Governing Law.
Any questions, claims, disputes or litigation concerning or arising from the Agreement shall be governed by the laws of the State
of California, United States of America, without giving effect to any federal or state conflicts of laws principles or doctrines
of the United States, or any nation state.

 

9.3Assignment;
Binding Effect. This Agreement is not assignable by any Party without the prior written consent of the other Party. Notwithstanding
the foregoing, Amarantus shall be permitted, without the consent of MDx, to assign this Agreement (a) to its Affiliates or to perform
this Agreement, in whole or in part, through its Affiliates, provided that Amarantus shall be primarily liable and responsible
for performance by such Affiliate hereunder, or (b) to any successor or third Person that acquires all or substantially all of
the assets to which this Agreement relates by sale, transfer, merger, reorganization, operation of law or otherwise; provided
that the assignee agrees in writing to be bound to the terms and conditions of this Agreement. In the event of an assignment permitted
under this Section 10.6, the assigning Party shall notify the other Party in writing of such assignment. This Agreement
shall be binding upon and shall inure to the benefit of the Parties and their successors and permitted assigns. Any assignment
not in accordance with this Section 9.3 shall be null and void.

 

    	Page 6
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

 

9.4Successors
and Assigns. This Agreement shall bind and shall inure to the benefit of the parties hereto and their respective assigns, transferees,
and successors.

 

9.5Counterparts;
Facsimile. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which, when
taken together as a whole, shall constitute one and the same instrument. Facsimile copies of signed signatures pages shall be deemed
binding originals.

 

9.6Notices.
Any notices required or permitted hereunder shall be given in writing either (a) through personal delivery by courier with
tracking capabilities or otherwise, (b) by telecopy or other electronic medium, or (c) by deposit in United States mail.
All notices shall be deemed given or made (x) on the date delivered if delivered personally, by courier or otherwise, (y) on the
date initially received, if delivered by telecopy or other electronic medium followed by confirmation by personal delivery or registered
or certified mail, or (z) on the third business day after it is mailed.

 

9.7Severability.
If any provision in this Agreement shall be found or be held to be invalid or unenforceable, then the meaning of said provision
shall be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would
save such provision, it shall be severed from the remainder of this Agreement which shall remain in full force and effect unless
the severed provision is essential and material to the rights or benefits received by any party. In such event, the parties shall
use best efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement which most nearly affects
the parties’ intent in entering into this Agreement.

 

9.8No-Third Party
Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their permitted assigns and nothing herein,
express or implied, is intended to or will confer upon any other person or entity any legal or equitable right, benefit or remedy
of any nature whatsoever under or by reason of this Agreement.

 

9.9Time of the
Essence. With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

 

9.10Specific Performance.
The Parties agree that irreparable damages would occur in the event any provision of this Agreement is not performed in accordance
with the terms hereof and each of the Parties will be entitled to specific performance of the terms hereof or injunctive relief,
in addition to any other remedy at law or in equity that may be available under applicable Law.

 

9.11Expenses.
Except as otherwise expressly provided in this Agreement, whether or not the transactions contemplated hereby are consummated,
each Party hereto will pay its own costs and expenses incurred in connection with the negotiation, execution and closing of this
Agreement.

 

9.12Announcement.
Following the Closing, MDx will not issue any press release or otherwise make any public statement with respect to this Agreement
and the transactions contemplated hereby without the prior consent of Amarantus, except as may be required by applicable Law. Amarantus
may issue a press release or otherwise make public statements with respect to this Agreement and the transactions contemplated
hereby without MDx’s consent.

 

[Remainder of Page
Intentionally Left Blank]

 

    	Page 7
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

IN WITNESS WHEREOF,
MDx and Amarantus have caused this Agreement to be signed by their respective officers thereunto duly authorized, all as of the
date first written above.

 

 

	“MDx”	 	Memory Dx, LLC
		 	an Arizona limited liability company
	 	 	 
	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 
	 	 	 
	 	 	 
	“Amarantus”	 	Amarantus Bioscience Holdings Inc.
		 	a Nevada corporation
	 	 	 
	 	 	By:	 
	 	 	Name:	 Marc E. Faerber
	 	 	Title: 	V.P. Finance

 

 

 

Signature Page
to Asset Purchase Agreement

    	Page 8
EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

SCHEDULE 1

 

EXCLUDED ASSETS

 

 

 

Licensing Agreement between
GW Medical Technologies, LLC (now MDx) and the University of Leipzig, dated May 22, 2003, as amended.

 

 

 

 

 

 

 

 

 

 

 

Page 1 of 13

    	EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

EXHIBIT A

 

FORM OF BILL OF SALE

 

 

 

    	EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

BILL OF SALE AND CONVEYANCE

 

This BILL OF SALE AND
CONVEYANCE is made and entered into as of July 16, 2010, by and among Memory Dx, LLC, a [] corporation (the “MDx”)
and Amarantus Bioscience Holdings, Inc., a Delaware corporation (the “Amarantus”).

 

R E C I T A L S

 

A.MDx and Amarantus
are parties to an Asset Transfer and Assignment Agreement dated as of April [], 2014 (the “Asset Purchase Agreement”)
pursuant to which MDx agreed to sell, and Amarantus and agreed to purchase, the “Transferred Assets,” as set forth
in Section 1 of the Asset Purchase Agreement.

 

B.MDx and Amarantus
now desire to carry out the intent and purpose of the Asset Purchase Agreement by MDx’s execution and delivery to Amarantus
of this instrument evidencing the sale, conveyance, assignment, transfer and delivery to Amarantus of certain of the Transferred
Assets.

 

C.It is the intent
of the parties hereto to reflect the transfer of title to the Transferred Assets owned by MDx by the execution and delivery of
this Bill of Sale and Conveyance by MDx to Amarantus.

 

NOW, THEREFORE, in
consideration of the covenants, representations, warranties and mutual agreements set forth herein and in the Asset Purchase Agreement
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, MDx and Amarantus hereby
agree as follows:

 

1.All capitalized
terms used as defined terms and not otherwise defined herein shall have the meanings set forth in the Asset Purchase Agreement.

 

2.MDx does hereby,
effective from and after the Closing, sell, convey, assign, transfer and deliver unto Amarantus, MDx’s entire right, title
and interest in, to and under the Transferred Assets set forth in Exhibit A-1 hereto.

 

3.This instrument
shall be binding upon and shall inure to the benefit of the respective successors, assigns and transferees of MDx and Amarantus.

 

4.In the event
that any provision of this Bill of Sale and Conveyance is construed to conflict with a provision of the Asset Purchase Agreement,
the provision in the Asset Purchase Agreement shall be deemed controlling.

 

5.This instrument
shall be construed and enforced in accordance with the laws (other than the conflict of law rules) of the State of California.

 

6.This Bill of
Sale and Conveyance may be executed in one or more counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument.

 

 

 

    	EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

 

 

IN WITNESS WHEREOF,
the parties hereto have caused this Bill of Sale and Conveyance to be executed and delivered by their duly authorized officers
as of the date first above written.

 

 

	 	 	Memory Dx, LLC
	 	 	
	 	 	 
	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	Amarantus Bioscience Holdings Inc.
	 	 	
	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title: 	

 

  

 

 

 

    	EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

    	 

    

EXHIBIT A-1

 

TRANSFERRED ASSETS

 

[NTD: To be updated
to reflect any changes to Section 1 of the APA]

 

1.The Transferred
Assets transferred hereby shall consist of all of MDx’s right, title and interest in and to all of the rights, properties,
goodwill and assets of MDx of every nature, kind and description, tangible and intangible, wherever located, whether or not carried
on the books of MDx, except those assets expressly identified as Excluded Assets on Schedule 1 to the Asset Purchase Agreement,
which shall remain with MDx. “LymPro Technology” means any and all cell-based technique for the detection, diagnosis
or prognostic testing related to any neurodegenerative disorder, including without limitation, Alzheimer’s Disease. The Transferred
Assets specifically include, without limitation:

 

1.1all
of the intellectual property owned by MDx as of the Closing Date (the “Intellectual Property”), including:

 

(a)any and all patents
and patent applications (respectively issued or filed throughout the world), owned by MDx as of the Closing Date, as well as any
extensions, divisions, continuations and continuation-in-parts thereof and any applications or patents that claim priority from
such patents and applications, including, without limitation, any foreign counterparts of such patents, in each case related to
the LymPro Technology;

 

(b)the copyrights
owned by MDx as of the Closing Date related to the LymPro Technology;

 

(c)all other intellectual
property and technology, including, without limitation, know-how, trade secrets, inventions (whether or not patented), data, techniques,
materials, clinical and pre-clinical protocols, designs, formulas, processes, procedures, methods, source code, software, databases,
works of authorship, and all documentation and information relating to the design, manufacture, testing, installation, operation,
repair, maintenance, support and use of the LymPro Technology;

 

(d)the right to sue
and recover damages for past, present and future infringement of any intellectual property.

 

1.2all
computers, hard drives, removable storage media and records incorporating the Intellectual Property

 

 

 

    	EXHIBIT 10-1 MEMORYDX ASSET PURCHASE AGMT FINAL.DOCX

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]